Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226622 · ClinicalTrials.gov registry record
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
A clinical trial of Wilson Disease, sponsored by Prime Medicine.
- Recruiting
- Registry status
- 30
- Enrollment target
- 7
- Study locations
NCT07226622 is a study of Wilson Disease that is actively recruiting participants, run by Prime Medicine. The registered enrollment target is 30 participants, below the 119-participant average among 4 other Wilson Disease trials with a reported enrollment target (75% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT07226622, a study of Wilson Disease, is actively recruiting participants, sponsored by Prime Medicine.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
The aim of this study is to inform and improve future clinical trials in Wilson Disease (WD) by better understanding how patients with WD are living with and managing the disease, and by identifying key factors that shape their decisions to participate in clinical research.
Conditions Studied
Study Locations (7)
California
- University of California Los Angeles Medical Center - Los Angeles
- University of California Davis Health - Sacramento
Connecticut
- Yale New Haven Hospital - New Haven
Illinois
- Northwestern University - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan Medicine - Ann Arbor
Texas
- American Research Corporation - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226622
The ClinicalTrials.gov registry entry for NCT07226622 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 4 other Wilson Disease trials with a reported enrollment target (75% lower). The listed sponsor is Prime Medicine, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Wilson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07226622 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT07226622 about?
NCT07226622 is a clinical study titled "Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial". The aim of this study is to inform and improve future clinical trials in Wilson Disease (WD) by better understanding how patients with WD are living with and managing the disease, and by identifying key factors that shape their decisions to participate in clinical research.
What is the current status of trial NCT07226622?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-12-29. Estimated completion is 2027-12.
What conditions does trial NCT07226622 study?
This clinical trial studies the following conditions: Wilson Disease.
Who is sponsoring clinical trial NCT07226622?
This trial is sponsored by Prime Medicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226622 being conducted?
This trial has 7 study locations across California, Connecticut, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wilson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Natural History of Wilson Disease
RECRUITING
-
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
RECRUITING
-
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
ACTIVE NOT RECRUITING · Phase 1
-
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.